Fremanezumab in Children and Adolescents with Episodic Migraine - Part 1

In part one of this two-part series, Dr. Tesha Monteith and Dr. Andrew Hershey summarize findings from the SPACE trial evaluating fremanezumab in adolescents and children with migraine.

Show citation:

Hershey AD, Szperka CL, Barbanti P, et al. Fremanezumab in Children and Adolescents with Episodic Migraine. N Engl J Med. 2026;394(3):243-252. doi:10.1056/NEJMoa2504546

Show transcript:

Dr. Tesha Monteith:

Hi, this is Tesha Monteith with the Neurology Minute. I'm here with Andrew Hershey, Professor of Pediatrics and Director of the Division of Neurology at Cincinnati Children's and the Children's Headache Center. We're here talking about his new paper published in the New England Journal of Medicine, Fremanezumab in Children and Adolescents with Episodic Migraine. Andrew, thank you for being on our Neurology Minutes.

Dr. Andrew Hershey:

Thank you for inviting me.

Dr. Tesha Monteith:

Can you summarize the findings of the space trial investigating Fremanezumab for adolescents and children with migraine?

Dr. Andrew Hershey:

This is one of the four monoclonal antibodies against CGRP, or it's this receptor that had been proven effective for adults. And it's the first one, the formazepam, that's been able to report its effectiveness in children and adolescents with less than 15 headache days per month. This study looked at over 200 children adolescents that were in a double-blinded randomized placebo controlled study. And reached its primary, as well as its secondary endpoint of a reduction compared to placebo. And the number of attacks of migraine per month, as well as a greater than 50% reduction in the number of headache attacks per month, with minimal to no side effects, the most notable side effect being injection site erythema.

Dr. Tesha Monteith:

Great. Thank you so much for providing that update. Do check out the full podcast for more details about his paper and the treatment of migraine in children and adolescents. This is Tesha Monteith. Thank you for listening to the Neurology Minute.

Det här avsnittet är hämtat från ett öppet RSS-flöde och publiceras inte av Podme. Det kan innehålla reklam.

Avsnitt(2009)

Updates in Neuroinfectious Disease - Part 5

In the fifth episode of this series, Dr. Paul Crane and Dr. Prashanth Ramachandran discuss dexamethasone and listeria meningitis.

8 Sep 4min

Updates in Neuroinfectious Disease - Part 4

In the fourth episode of this series, Dr. Paul Crane and Dr. Prashanth Ramachandran discuss the use of dexamethasone in the treatment of pneumococcal meningitis.

7 Sep 5min

Comparison of the Efficacy and Safety of Myasthenia Gravis Treatments - Part 1

In the first installment of this series, Dr. Aaron Zelikovich and Dr. Bhaskar Roy discuss how emerging treatments for myasthenia gravis compare to one another. Show citation: McLaren NP, Rosati M, Z...

4 Sep 1min

National Trends in Medicare Charges and Reimbursement for Inpatient Neurologic Care

Dr. Jason Crowell and Ka-Ho Wong discuss national trends in Medicare reimbursement for inpatient neurologic care. Show citation: Wong KH, Castillo M, King J, et al. National Trends in Medicare Charg...

3 Sep 2min

Updates in Neuroinfectious Disease - Part 3

In the third episode of this series, Dr. Paul Crane and Dr. Prashanth Ramachandran discuss HSV encephalitis and dexamethasone.

2 Sep 5min

Updates in Neuroinfectious Disease - Part 2

In part two of this series, Dr. Paul Crane and Dr. Prashanth Ramachandran discuss pegivirus-associated encephalomyelitis.

1 Sep 5min

Updates in Neuroinfectious Disease - Part 1

In part one of this series, Dr. Paul Crane and Dr. Prashanth Ramachandran discuss acute necrotizing encephalopathy.

31 Aug 4min

2026 Alzheimer's Association International Conference - Part 1

In part one of this series, Drs. Greg Cooper, Trey Bateman, and Gregg Day discussed key takeaways from the 2026 Alzheimer's Association International Conference, focusing on blood-based biomarkers, an...

27 Aug 1min